[
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026",
    "title": "Kvartalsrapport Q2 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a549985d90a9c3e03c64f2628a9fd36bb",
    "date": "2026-07-27",
    "period": "2026-q2",
    "form_type": "interim-report",
    "report_key": "2026:q2",
    "filename": "FINAL_-_26_JUL_AZN_2026_Q2_-_Announcement.pdf",
    "text_chars": 148994,
    "sha256": "49da44dc4c459daeb44d39186f1d0ea3a197ccd18b202f691782fa4a0c83753b",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html",
        "chars": 148994
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
    "title": "Kvartalsrapport Q1 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a2a52657347f9a897ecca69cecd31b015",
    "date": "2026-04-29",
    "period": "2026-q1",
    "form_type": "interim-report",
    "report_key": "2026:q1",
    "filename": "POST_DC_-_28_APR_AZN_2026_Q1_-_Announcement.pdf",
    "text_chars": 114348,
    "sha256": "9cd13c17549a1e83e860c6b713be2fd22f2d7e870c10ff485d067e2bb81b8d65",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
        "chars": 114348
      }
    ]
  },
  {
    "doc_id": "mfn-fallback-arsredovisning-2026",
    "title": "Årsredovisning 2026",
    "source": "MFN fallback",
    "source_class": "mfn",
    "source_url": "https://mfn.se/cis/a/astrazeneca/astrazeneca-filing-of-annual-report-on-form-20-f-with-the-us-securities-and-exchange-commission-e7642acb",
    "date": "2026-02-25",
    "period": "2026-annual",
    "form_type": "annual-report",
    "report_key": "2026:annual",
    "filename": "release.txt",
    "text_chars": 9770,
    "sha256": "4213b681def7f0bcb4dc2fc5cf00eb29424d35690292be7a464a48c457777cff",
    "url": "/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026",
    "txt_url": "/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026/part-001.html",
        "chars": 9770
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2025",
    "title": "Årsredovisning 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a7bfe2ec257ad4f4cb110977f3d64c512",
    "date": "2026-02-24",
    "period": "2025-annual",
    "form_type": "annual-report",
    "report_key": "2025:annual",
    "filename": "02245634.pdf",
    "text_chars": 2357,
    "sha256": "a381ef16b21d3c2400de8cb47412c2d68353513c8e441c7e6b581d16a26f97a5",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
        "chars": 2357
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
    "title": "Kvartalsrapport Q4 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "http://www.rns-pdf.londonstockexchange.com/rns/3227S_1-2026-2-9.pdf",
    "date": "2026-02-10",
    "period": "2025-q4",
    "form_type": "year-end-report",
    "report_key": "2025:q4",
    "filename": "http_www.rns-pdf.londonstockexchange.com_rns_3227S_1-2026-2-9.pdf",
    "text_chars": 138705,
    "sha256": "568ede7aadd8f7e50cc4b6eec6922dc3c9fff855e49eaa2516093e79fe8ac679",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
        "chars": 138705
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
    "title": "Kvartalsrapport Q3 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a6b0514be8a0eb722470815d6c48541c9",
    "date": "2025-11-06",
    "period": "2025-q3",
    "form_type": "interim-report",
    "report_key": "2025:q3",
    "filename": "11065940.pdf",
    "text_chars": 127823,
    "sha256": "de460cb4b01ef45d4df0b0a2bce97af47104fafef078983f3ecd5594fc0a97ad",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
        "chars": 127823
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
    "title": "Kvartalsrapport Q2 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ad088f09125d78d4ca4a8b44606420548",
    "date": "2025-07-29",
    "period": "2025-q2",
    "form_type": "interim-report",
    "report_key": "2025:q2",
    "filename": "H1_and_Q2_2025_results.pdf",
    "text_chars": 144742,
    "sha256": "bccbf955cce93458737d6e0691237335077ee0ef556b18b9daa56e5495ddb466",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
        "chars": 144742
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
    "title": "Kvartalsrapport Q1 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aceea43c3a8d3a0d6df16bd92a6ff0bc6",
    "date": "2025-04-29",
    "period": "2025-q1",
    "form_type": "interim-report",
    "report_key": "2025:q1",
    "filename": "04294155.pdf",
    "text_chars": 119801,
    "sha256": "24e40bba74661bdfda2252726f5d432768ab8195cc78150db849c00fd4e523dd",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
        "chars": 119801
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2024",
    "title": "Årsredovisning 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ab50172710d60f24ca9c9d9f8ae3eddb3",
    "date": "2025-02-18",
    "period": "2024-annual",
    "form_type": "annual-report",
    "report_key": "2024:annual",
    "filename": "02188545.pdf",
    "text_chars": 2393,
    "sha256": "6005163cf2b1f4e02004c48c7b56020ea7984bc886f4b099f1aa9387797c20fa",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
        "chars": 2393
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
    "title": "Kvartalsrapport Q3 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a7d85580eb0dd41ae6cdf74ab1a011e2e",
    "date": "2024-11-12",
    "period": "2024-q3",
    "form_type": "interim-report",
    "report_key": "2024:q3",
    "filename": "11125809.pdf",
    "text_chars": 137431,
    "sha256": "42cf108fb5d0339a59dc2451cf13694331a0eb6e135fdf48a0bc99e46e99e281",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
        "chars": 137431
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
    "title": "Kvartalsrapport Q2 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a9a9ed29bfd6832e30f8d5ad48b31be44",
    "date": "2024-07-25",
    "period": "2024-q2",
    "form_type": "interim-report",
    "report_key": "2024:q2",
    "filename": "07258987.pdf",
    "text_chars": 155942,
    "sha256": "e10f937783d2e317ed8d9ec7787f1ec1bd6eec0a1e670d13d4d7e774d999b947",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
        "chars": 155942
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2023",
    "title": "Årsredovisning 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aefd2ab38ab7fc19764b798b153be4f7d",
    "date": "2024-02-20",
    "period": "2023-annual",
    "form_type": "annual-report",
    "report_key": "2023:annual",
    "filename": "02201886.pdf",
    "text_chars": 2641,
    "sha256": "c7a4fef5239d72026465eae25c5cce38739473ea26853573757bc43f4d2f0f75",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
        "chars": 2641
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
    "title": "Kvartalsrapport Q3 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a9fdf538c261c8884d36da766d1ac9718",
    "date": "2023-11-09",
    "period": "2023-q3",
    "form_type": "interim-report",
    "report_key": "2023:q3",
    "filename": "11091395.pdf",
    "text_chars": 149318,
    "sha256": "bf9cb364e4c58495b8c5fe38fd83bcca98ce79007acfd745f1f5c9702aa68b12",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
        "chars": 149318
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
    "title": "Kvartalsrapport Q2 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ab79b52fc3e3f6b753469465c818d7410",
    "date": "2023-07-28",
    "period": "2023-q2",
    "form_type": "interim-report",
    "report_key": "2023:q2",
    "filename": "07289280.pdf",
    "text_chars": 158635,
    "sha256": "f02f5f8ba9057106933d59b5005aa211b360551919be8f561e3c8b973a841a24",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
        "chars": 158635
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
    "title": "Kvartalsrapport Q1 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a032c58d210d62745c6d35441c52993b2",
    "date": "2023-06-01",
    "period": "2023-q1",
    "form_type": "interim-report",
    "report_key": "2023:q1",
    "filename": "06017034.pdf",
    "text_chars": 2351,
    "sha256": "011c7d3ad087ef585142fcc7b59cc76e4831cf91ef22cc2479af54629cd16ce6",
    "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
        "chars": 2351
      }
    ]
  },
  {
    "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
    "title": "MFN bolagssida och bolagsmetadata",
    "source": "MFN",
    "source_class": "mfn",
    "source_url": "https://mfn.se/all/a/astrazeneca",
    "date": null,
    "period": null,
    "form_type": "company-page",
    "report_key": null,
    "filename": "company.txt",
    "text_chars": 17911,
    "sha256": "8ff8dc15e3900dc647d1bbe1eacfae956eb008816ce839e05e323c584442cf01",
    "url": "/company/astrazeneca-plc/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "txt_url": "/company/astrazeneca-plc/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/astrazeneca-plc/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
        "chars": 17911
      }
    ]
  }
]